本公司第五届董事会第十次会议（以下简称"会议"）的通知和 材料于 2025 年 6 月 9 日以书面方式通知全体董事，会议于 2025 年 6 月 27 日在北京市西城区西长安街 88 号中国人保大厦以现场会议方式 召开。会议应出席董事 12 名，现场出席 10 名，委托出席 2 名。丁向 群董事、赵鹏董事委托肖建友董事出席会议并表决。会议由肖建友董 事主持。监事会成员及部分高级管理层成员列席了会议。会议的召开 符合《中华人民共和国公司法》等相关法律、行政法规、部门规章和 《中国人民保险集团股份有限公司章程》的规定，会议合法、有效。 第五届董事会第十次会议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 证券代码：601319 证券简称： 中国人保 公告编号：临 2025-022 中国人民保险集团股份有限公司 经与会董事审议并表决，形成以下会议决议： 公司董事会同意选举宋洪军先生、徐丽娜女士和杨长缨女士为公 司第五届董事会战略与投资委员会委员。 表决结果：12 票同意，0 票反对，0 票弃权。 四、审议通过了《关于选举公 ...

EF001 | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this | | | --- | --- | | howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement. | announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss | | Cash Dividend Announcement for Equity Issuer | | | Instrument | Equity issuer | | Issuer name | The People's I ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 喻 強 宋洪軍 1339 董事名單與其角色和職能 一、執行董事 丁向群 （董事長） 趙 鵬 （副董事長） 肖建友 二、非執行董事 王清劍 苗福生 王少群 三、獨立非執行董事 邵善波 徐麗娜 王鵬程 高平陽 - 1 - 四、董事會專業委員會 | 董事會下設五個董事會專業委員會，各董事會專業委員會的組成如下： | | --- | | | 委員會 | | 風險管理與 | | | | | --- | --- | --- | --- | --- | --- | --- | | | | 戰略與投資 | 消費者權益 | 審計 | 提名薪酬 | 關聯交易 | | 董事 | | 委員會 | 保護委員會 | 委員會 | 委員會 | 控制委員會 | | 丁向群 | | C | | | | | | 趙 鵬 | | | C | | | | | 肖建友 | | | | | | M | | 王清劍 | | M | | M | | | ...

FANGDA PARTNERS http://www.fangdalaw.com 关于中国人民保险集团股份有限公司 2024 年度股东会的法律意见书 致：中国人民保险集团股份有限公司 上海市方达（北京）律师事务所（以下简称"本所"）是具有中华人民共和国 境内法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席中 国人民保险集团股份有限公司（以下简称"公司"）2024 年度股东会（以下简称"本 次股东会"），并就本次股东会的召集和召开程序、参与表决和召集会议人员的资 格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》《上市公司股东会规则》及其他相关中华人民共和国境内 已公开颁布并生效的法律、法规、规章及规范性文件（以下合称"中国法律法规"， 仅为本法律意见书说明之目的，不包括中国香港特别行政区、中国澳门特别行政 区和中国台湾地区的法律、法规）以及《中国人民保险集团股份有限公司章程》 （以下简称"《公司章程》"）的规定出具。 本法律意见书仅就本次股东会的召集和召开程序、出席会议人员、召集人、 表决程序是否符 ...

证券代码：601319 证券简称： 中国人保 公告编号：临 2025-022 中国人民保险集团股份有限公司 第五届董事会第十次会议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 本公司第五届董事会第十次会议（以下简称"会议"）的通知和 材料于 2025 年 6 月 9 日以书面方式通知全体董事，会议于 2025 年 6 月27日在北京市西城区西长安街88号中国人保大厦以现场会议方式 召开。会议应出席董事 12 名，现场出席 10 名，委托出席 2 名。丁向 群董事、赵鹏董事委托肖建友董事出席会议并表决。会议由肖建友董 事主持。监事会成员及部分高级管理层成员列席了会议。会议的召开 符合《中华人民共和国公司法》等相关法律、行政法规、部门规章和 《中国人民保险集团股份有限公司章程》的规定，会议合法、有效。 经与会董事审议并表决，形成以下会议决议： 一、审议通过了《关于制定<中国人民保险集团股份有限公司合 规管理办法>的议案》 表决结果：12 票同意，0 票反对，0 票弃权。 二、审议通过了《关于制定<中国人民保险集团投资资产 ...

Core Viewpoint - The insurance sector in A-shares and Hong Kong stocks has shown significant growth, with major companies experiencing substantial stock price increases, driven by a shift towards participating insurance products and regulatory guidance aimed at stabilizing the market [1][2][3]. Group 1: Market Performance - On June 25, A-shares saw all three major indices rise, with the Shanghai Composite Index increasing by 1.04%, reaching a new high for the year [1]. - The insurance sector led the gains, with companies like New China Life and China Pacific Insurance rising over 3%, and China Life increasing by more than 2% [1]. - In Hong Kong, insurance stocks also performed well, with China Pacific Insurance rising over 5% and New China Life and China Taiping both increasing by over 4% [1]. Group 2: Regulatory Environment - The China Banking and Insurance Regulatory Commission issued guidelines to life insurance companies, emphasizing prudent management and discouraging excessive competition in dividend levels [1][2]. - The guidelines aim to stabilize the market by ensuring that companies do not artificially inflate dividend levels, which could disrupt the insurance market [1][2]. Group 3: Industry Trends - The transition towards participating insurance products is expected to begin in 2025, with a focus on floating yield products [2]. - Analysts predict that the adjustment of preset interest rates and the integration of individual insurance reporting will impact premium growth rates, with a potential increase in the attractiveness of participating insurance [2]. - The regulatory measures are seen as beneficial for controlling the floating cost levels of participating insurance, thereby reducing long-term risks associated with interest rate differentials [2]. Group 4: Future Outlook - Analysts expect that the new business value (NBV) growth rate will decline compared to 2024, but the quality of operations is anticipated to improve [3]. - The insurance sector is viewed as having long-term investment potential, with the ability to withstand market fluctuations and support capital market development [3]. - The target demographic for insurance products is shifting towards wealthier individuals from the 60s and 70s, with participating insurance products likely to become central in wealth management [3].

Core Viewpoint - The Ministry of Agriculture and Rural Affairs of China has announced the top ten innovative financial support models for agriculture in 2024, with "China Pacific Insurance's comprehensive agricultural insurance products supporting farmland protection and quality improvement" being recognized as one of the innovative models [1] Group 1: Innovative Products - China Pacific Insurance has developed three major insurance products: quality defect liability insurance for high-standard farmland construction, comprehensive insurance for farmland facility damage, and soil fertility index insurance, providing comprehensive protection for transforming ordinary farmland into high-yield farmland [2] - The quality defect liability insurance for high-standard farmland construction covers material damage caused by quality defects and natural disasters, as well as repair costs due to operational failures [2] - As of the end of 2024, these three agricultural insurance products have been promoted in all 31 provinces, providing risk coverage of 14.4 billion yuan for quality defect liability insurance, 2.9 billion yuan for comprehensive insurance, and over 800 million yuan for soil fertility index insurance, with total claims exceeding 135 million yuan [3] Group 2: Service Innovation - China Pacific Insurance has introduced professional services to enhance farmland facility management, intervening throughout the entire process of farmland construction, management, and maintenance [4] - The company has established specialized service teams in Sichuan Province to conduct risk assessments and provide maintenance suggestions, resulting in the identification of 585 risk points and 164 hidden risks in completed projects in 2024 [4] Group 3: Technology Empowerment - The company is enhancing service efficiency through technology, developing a "Farmland Management" platform that integrates risk control technology for digital processes and online operations [5][6] - The platform allows for the recording of insured farmland project information and facilitates regular inspections and risk reporting through a mobile app [6] Group 4: Risk Reduction - China Pacific Insurance is shifting its insurance model from traditional loss compensation to risk reduction, exploring integrated service mechanisms that combine preemptive measures and post-event compensation [7] - In Liaoning Province, the company is promoting soil quality improvement by providing farmers with free materials for soil enhancement and technical guidance from third-party soil restoration companies [7]

Group 1: Core Insights - The report highlights the integration of big data and AI in providing comprehensive talent compensation data analysis and management solutions, covering over 1 billion talent data points and serving more than 30,000 corporate clients [1][13][16]. Group 2: Sample Distribution - Company size distribution shows that 28.3% of companies have fewer than 100 employees, 23.9% have 100-500 employees, 7.8% have 500-1000 employees, and 40.2% have over 1000 employees [2][29]. - The majority of companies are privately owned, accounting for 96.3%, while state-owned and listed companies represent a smaller share [2][32]. - Major company headquarters are concentrated in first-tier cities like Shanghai, Beijing, and Shenzhen, with East, North, and South China being the primary regions [2]. Group 3: Human Resource Indicators - The salary increase rate for the technology finance sector is projected to be 0.2% for 2024, with a decrease of 0.2% over the past 12 months and a forecast of 0% for 2025 [4][38]. - The turnover rate in the technology finance sector is expected to be 18.3% in 2024, down from 27.6% in 2023, indicating an improvement in employee retention [5][51]. - The average starting salary for 2024 graduates is 9,222 yuan, with higher salaries for those with advanced degrees, particularly in IT and finance roles [5][53]. Group 4: Labor Demand - Recruitment trends indicate a decrease in hiring volume to 5,799 in Q2 2025, a 43.6% decline, while recruitment salaries have increased by 1% [7]. - In the past month, Xi'an has seen the highest recruitment volume and salaries, while some cities have experienced declines in hiring [8]. - Popular job functions include credit business, consulting services, and investment management, with significant salary increases in market operations and data analysis roles [8]. Group 5: Benefits Insights - 90% of companies have a per capita benefits budget exceeding 600 yuan, with specific data available for key holidays like Spring Festival and Mid-Autumn Festival [9]. Group 6: Popular Position Salaries - In first-tier cities, popular positions such as financial product managers and risk management specialists have clear salary data across different percentiles, with algorithm positions reaching an annual total cash income of 372,860 yuan at the 90th percentile [10].

Core Viewpoint - The Chinese government has issued new guidelines aimed at enhancing the insurance industry's service capabilities and risk management, particularly in health insurance, which is expected to drive product innovation and market expansion [1]. Group 1: Policy and Market Response - The State Council's new guidelines are seen as a significant policy shift for the insurance industry, focusing on improving health insurance services and expanding coverage [1]. - Major insurance companies are actively upgrading their products and services in response to evolving market demands, with China Life Insurance and Ant Group launching upgraded versions of their health insurance products [1][2]. Group 2: Product Upgrades - China Life Insurance has upgraded its "Good Insurance·Long-term Medical (Flagship Version 2025)" and "Good Insurance·Senior Long-term Medical (2025 Version)" products, enhancing their service offerings in advanced hospital networks and health management [2]. - The upgraded products now include coverage for 340 international special departments and 121 high-end private hospitals, breaking the traditional limitations of medical insurance [2]. - The advanced medical equipment and drug list has been expanded from 202 to 1501 items, allowing for 100% reimbursement with zero deductible for eligible treatments [2]. Group 3: Health Management Services - The new offerings include a comprehensive health management service that adds a "Family Doctor" module, providing 24/7 online consultations and chronic disease management [3]. - This integration of insurance and health management reflects a shift from traditional reimbursement models to a more holistic approach to health care, aligning with national policy goals [3].

Core Viewpoint - China People's Health Insurance Co., Ltd. has upgraded its long-term medical insurance products in collaboration with Ant Financial to support the construction of a multi-level medical system in the country [1][2]. Group 1: Product Features - The upgraded products include "Good Medical Insurance · Long-term Medical (Flagship Version 2025)" and "Good Medical Insurance · Elderly Long-term Medical (2025 Version)" [1]. - In the field of tumor treatment, the new products have expanded the network of proton therapy institutions from the original Shanghai Proton and Heavy Ion Hospital to include 9 additional locations in Beijing, Guangzhou, and others, increasing accessibility to advanced radiation therapy by 10 times [1]. - The flagship product now covers 340 international special departments in hospitals and 121 high-end private hospitals, allowing users to enjoy international-level medical environments at affordable prices [1]. Group 2: Coverage and Reimbursement - Both products guarantee renewal for general medical expenses for 20 years and provide lifetime renewal for cancer and 11 types of cardiovascular diseases, offering stable protection for patients requiring long-term treatment [2]. - The reimbursement mechanism for general diseases employs a "segmented reimbursement" approach, where expenses under 10,000 yuan are reimbursed at 30%, and expenses exceeding 10,000 yuan are reimbursed at 100%. For cancer and the specified cardiovascular diseases, the reimbursement is at 100% [2]. - The "Good Medical Insurance · Elderly Long-term Medical (2025 Version)" includes an innovative "Advanced Hospital Insurance for Severe Malignant Tumors" to address the challenges elderly patients face in accessing quality medical resources, thereby reducing the time from diagnosis to treatment for cancer patients [2].